Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Randomized, Multicentre Trial to Evaluate Efficacy and Safety of a 24-Week Course of PEG-Interferon Alpha-2b Versus a 12-Week Course of PEG-Interferon Alpha-2b Alone or Plus Ribavirin in Patients With Acute Hepatitis C.

Next Previous
Trial Profile

An Open, Randomized, Multicentre Trial to Evaluate Efficacy and Safety of a 24-Week Course of PEG-Interferon Alpha-2b Versus a 12-Week Course of PEG-Interferon Alpha-2b Alone or Plus Ribavirin in Patients With Acute Hepatitis C.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 18 Jan 2014 Results published in the Hepatology.
  • 30 Jan 2012 Actual patient number changed from 137 to 130 as reported by ClinicalTrials.gov.
  • 10 Feb 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top